AZ 628

製品コードS2746

AZ 628化学構造

分子量(MW):451.52

AZ628は一種の新たなpan-Raf阻害剤で、無細胞試験でBRAF、BRAFV600Eとc-Raf-1に作用する時のIC50値が105 nM、34 nMと29 nMにそれぞれ分かれることですが、VEGFR2、DDR2、Lyn、Flt1とFMS等も抑制します。

サイズ 価格(税別) 在庫  
JPY 44820.00 あり
JPY 24900.00 あり
JPY 78020.00 あり

カスタマーフィードバック(2)

  • A375 cells were infected with the indicated shRNAs/ORFs. In parallel to the above, cells were also treated with 0.2 uM AZ628 for 16 h, cell lysates were analyzed by Western blotting for the indicated proteins.

    Cancer Discov 2013 3(3), 350-62. AZ 628 purchased from Selleck.

    Enzymatic activity of RIP3 from Abcam, the concentration-effect relationship of RIP3 inhibition by the tested protein kinase inhibitors and the mode of action of RIP3 inhibition by dabrafenib. The RIP3 inhibition rates of AZ628 at different concentrations were measured by the luminescent RIP3 assay. The data (mean ?SD from 3 independent experiments) were presented as the Lineweaver-Burk plots using Graphpad Prism 5.

    Cell Death Dis 2014 5, e1278. AZ 628 purchased from Selleck.

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 AZ628は一種の新たなpan-Raf阻害剤で、無細胞試験でBRAF、BRAFV600Eとc-Raf-1に作用する時のIC50値が105 nM、34 nMと29 nMにそれぞれ分かれることですが、VEGFR2、DDR2、Lyn、Flt1とFMS等も抑制します。
ターゲット
C-Raf-1 [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
29 nM 34 nM 105 nM
体外試験

AZ628 prevents activation of number of tyrosine protein kinases including VEGFR2, DDR2, Lyn, Flt1, FMS and others. AZ628 suppresses anchorage-dependent and -independent growth, gives rise to cell cycle arrest, and induces apoptosis in colon and melanoma cell lines harboring B-RafV600E mutation. The profile of AZ628 cross-reactivity suggests that similar to sorafenib, AZ628 may be antiangiogenic based on prevention of VEGFR2. [1] AZ628-resistant clones are approximately 100-fold more resistant to AZ628 than the parental cell line, exhibiting IC50 of approximately 10 μM, compared with 0.1 μM for the parental cell line. Effective suppression of p-ERK1/2 levels is observed in the M14 parental cell line following treatment with increasing concentrations of AZ628. AZ628-resistant clones express elevated CRAF. Elevated CRAF expression is a potential mechanism of acquired resistance to continuous AZ628 exposure, resulting in sustained activation of ERK1/2. p-ERK1/2 activity is not significantly inhibited by exposure to AZ628 in one of these three AZ628-insensitive cell lines (Wm1552C). Unlike in the AZ628-resistant M14 cells in which AZ628 fails to suppress the activation of ERK, AZ628 treatment efficiently attenuates ERK activation in the NRAS mutant melanoma cells.[2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
ACN cell NF;YUVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWrOS|JnUW6qaXLpeIlwdiCxZjDoeY1idiCDQ16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlExOSCwTR?= NGjzN4JUSU6JRWK=
SH-4 cell MlnmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVHKVJNWUW6qaXLpeIlwdiCxZjDoeY1idiCVSD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOSCwTR?= NYrocnlvW0GQR1XS
LB2518-MEL cell Mnz4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEnQTXBKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkWxPE1OTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke2JI5O NEn3VG1USU6JRWK=
A101D cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mmn1TY5pcWKrdHnvckBw\iCqdX3hckBCOTBzRDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPFIhdk1? MV;TRW5ITVJ?
HT-144 cell Mo\6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIHuVJNKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUG0OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPjFibl2= M2\5N3NCVkeHUh?=
SIG-M5 cell NFHaWJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVvJcohq[mm2aX;uJI9nKGi3bXHuJHNKTy2PNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuOFUhdk1? NFTiS2hUSU6JRWK=
DU-4475 cell Mm\wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGTWPIpKdmirYnn0bY9vKG:oIHj1cYFvKESXLUS0O|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5{MzDuUS=> M2ThNnNCVkeHUh?=
A375 cells NYX3VXFMTnWwY4Tpc44h[XO|YYm= NHTPdHg4PSCvaX7z NF3kUW5KdmirYnn0bY9vKG:oIFLSRWYhXjZyMFWgcZV1[W62LX3l[IlifGWmIFXST{BxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gRVM4PSClZXzsd{Bi\nSncjC3OUBucW6|LDDJR|UxRTBwMEG1JO69VQ>? MU[yN|M6QDR3Mx?=
OCI-AML2 cell MnHxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MknITY5pcWKrdHnvckBw\iCqdX3hckBQS0lvQV3MNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODF5zszN NFvp[mVUSU6JRWK=
COLO-829 cell M{jobGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3nKZmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz24Nlkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zPS54NTDuUS=> MnTVV2FPT0WU
PSN1 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkPDTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkeuN|chdk1? NEfIbVRUSU6JRWK=
UACC-257 cell NVP2Rnk{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXz6fng3UW6qaXLpeIlwdiCxZjDoeY1idiCXQVPDMVI2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJ5LkS5JI5O NVnh[GwyW0GQR1XS
RKO cell MoLCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnzrTY5pcWKrdHnvckBw\iCqdX3hckBTU09iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Nz62O{BvVQ>? NFy5WVRUSU6JRWK=
MMAC-SF cell M{W2fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEXO[XNKdmirYnn0bY9vKG:oIHj1cYFvKE2PQVOtV2Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01OC5yNzDuUS=> NF;1XGRUSU6JRWK=
Calu-6 cell M37MTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNidHVvNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWxMlQ4KG6P NIruPWRUSU6JRWK=
LS-513 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH[2OlZKdmirYnn0bY9vKG:oIHj1cYFvKEyVLUWxN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVc1NjF3IH7N MYnTRW5ITVJ?
NOS-1 cell NH[3XJVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkTzTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmyMlY2KG6P M3;EbnNCVkeHUh?=
SW872 cell NWnEOIVbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH7DfopKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVYvPDhibl2= MYrTRW5ITVJ?
KMOE-2 cell NIXpWmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mmj4TY5pcWKrdHnvckBw\iCqdX3hckBMVU:HLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNVUvQDhibl2= NVTlSZM{W0GQR1XS
MZ7-mel cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJG1bPy2vZXygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNVcvOjdibl2= NFnEc2FUSU6JRWK=
CGTH-W-1 cell NFf5WIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVIyNjNibl2= MlLVV2FPT0WU
CP66-MEL cell NHnDbHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUXJcohq[mm2aX;uJI9nKGi3bXHuJGNRPjZvTVXMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMyNjd4IH7N M3XRS3NCVkeHUh?=
K5 cell M3zBSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUjs[IZvUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGzOE4zKG6P MV3TRW5ITVJ?
HL-60 cell NFLYT5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{PmSWlvcGmkaYTpc44hd2ZiaIXtZY4hUExvNkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOVQvPDFibl2= M2TVcXNCVkeHUh?=
ONS-76 cell MnftS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX;CWFk4UW6qaXLpeIlwdiCxZjDoeY1idiCRTmOtO|Yh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPjZwNkKgcm0> NEPkUYJUSU6JRWK=
NB69 cell NGn5OHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1zkcGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5NU4{OSCwTR?= NEX0dGtUSU6JRWK=
LAMA-84 cell MojPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIfEd|FKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yQTJwNEKgcm0> M3:wU3NCVkeHUh?=
EM-2 cell  MoqzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGT6WGNKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPVUvQTFibl2= NXewNoZRW0GQR1XS
IST-MEL1 cell MojnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX7Me25VUW6qaXLpeIlwdiCxZjDoeY1idiCLU2StUWVNOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJyND6xN{BvVQ>? NHS0cWNUSU6JRWK=
HCC2998 cell NGC2cWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVvJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ7OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzOTh5IN88US=> MlXPV2FPT0WU
GDM-1 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NG[2XYlKdmirYnn0bY9vKG:oIHj1cYFvKEeGTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOjl2NzFOwG0> NHfTd3RUSU6JRWK=
MZ1-PC cell M1rufWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1;qW2lvcGmkaYTpc44hd2ZiaIXtZY4hVVpzLWDDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPzl7OTFOwG0> M{ftSnNCVkeHUh?=
BB49-HNC cell M3S1TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKGi3bXHuJGJDPDlvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PTF6IN88US=> MlPhV2FPT0WU
D-392MG cell NY\obYpVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4TyTGlvcGmkaYTpc44hd2ZiaIXtZY4hTC1|OULNS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzV4MEeg{txO NXLDcoV2W0GQR1XS
697 cell M37P[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4C4VWlvcGmkaYTpc44hd2ZiaIXtZY4hPjl5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{[zMlg5KM7:TR?= M{TOUnNCVkeHUh?=
ML-2 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4\UfWlvcGmkaYTpc44hd2ZiaIXtZY4hVUxvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO2PE45PiCwTR?= NUjKR5dTW0GQR1XS
MEG-01 cell NVSyOHkyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NY\NTG5qUW6qaXLpeIlwdiCxZjDoeY1idiCPRVetNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN5NjFOwG0> MnLGV2FPT0WU
SK-MEL-1 cell M3TLZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn3pTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzh|NkKg{txO NUSyfHl7W0GQR1XS
KS-1 cell NHvq[GxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFvCOGZKdmirYnn0bY9vKG:oIHj1cYFvKEuVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM6OzN5IN88US=> M1nVT3NCVkeHUh?=
NB14 cell NWDxcmF5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX;6VWpkUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41QTN|MTFOwG0> NEnydlNUSU6JRWK=
NCI-H747 cell Ml7YS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEG2V4NKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC53ME[zO{DPxE1? M3\Rd3NCVkeHUh?=
K-562 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPBTY5pcWKrdHnvckBw\iCqdX3hckBMNTV4MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOlY3QTVizszN NGLWXopUSU6JRWK=
NCI-H1648 cell Ml3sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV3SdGNlUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLk[3NlY3KM7:TR?= NI[0WFFUSU6JRWK=
LAN-6 cell Ml\tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGxCVi14IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD62PFI{PiEQvF2= M4DBWnNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

お薦めの試験操作(参考用のみ)

細胞試験: [1]
+ 展開
  • 細胞株: M14 expressing the V600E BRAF mutation
  • 濃度: 0.01-10 μM
  • 反応時間: Overnight
  • 実験の流れ: Approximately 0.5-2.5 × 105 M14 cells are seeded in 12 or 24 - well plates, respectively, in medium supplemented with 5% FBS. After overnight incubation, the cells are treated with various concentrations of AZ628. Fresh medium and drug is replaced every 2 days until the untreated control wells reached confluence. At this time-point, the media is removed and the cells are fixed in 4% formaldehyde in PBS for 20 minutes at room temperature. Cells are then washed twice with PBS and stained with a 1:5000 solution of the fluorescent nucleic acid stain Syto60. Quantitation of fluorescent signal intensity is carried out at 700 nm, using an Odyssey Infrared Imager. Each experiment is performed in quadruplicate and the results shown represent the average of the four values compared to untreated wells. Error bars represent standard deviation of the 4 values from the mean. High-throughput cell growth/viability assays are performed.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 90 mg/mL (199.32 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 451.52
化学式

C27H25N5O2

CAS No. 878739-06-1
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Raf信号経路図

Raf Inhibitors with Unique Features

相関Raf製品

Tags: AZ 628を買う | AZ 628 ic50 | AZ 628供給者 | AZ 628を購入する | AZ 628費用 | AZ 628生産者 | オーダーAZ 628 | AZ 628化学構造 | AZ 628分子量 | AZ 628代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID